Silence Therapeutics (SLN) Income towards Parent Company (2024 - 2026)

Silence Therapeutics (SLN) has 3 years of Income towards Parent Company data on file, last reported at -$15.0 million in Q1 2026.

• For the quarter ending Q1 2026, Income towards Parent Company rose 47.57% year-over-year to -$15.0 million; the trailing twelve-month figure through Mar 2026 stood at -$75.0 million (down 25.98% YoY), and the FY2025 full-year result was -$88.6 million, down 165.72% from the prior year.
• Income towards Parent Company fell to -$15.0 million in Q1 2026, from -$11.8 million in the prior quarter.
• In the past five years, Income towards Parent Company ranged from a high of $24.3 million in Q4 2024 to a low of -$35.5 million in Q3 2024.
• A 3-year average of -$15.2 million and a median of -$19.8 million in 2024 frame the typical range for Income towards Parent Company.
• Across the five-year window, Income towards Parent Company sank 1134.0% in 2025 and surged 47.57% in 2026, its largest moves.
• Tracing SLN's Income towards Parent Company over 3 years: stood at $24.3 million in 2024, then tumbled by 148.51% to -$11.8 million in 2025, then retreated by 27.08% to -$15.0 million in 2026.
• Business Quant data shows SLN's Income towards Parent Company at -$15.0 million in Q1 2026, -$11.8 million in Q4 2025, and -$21.0 million in Q3 2025.